{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T16:02:35Z","timestamp":1648915355845},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.medcli.2013.04.023","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T20:15:39Z","timestamp":1371759339000},"page":"91-92","source":"Crossref","is-referenced-by-count":0,"title":["Independencia transfusional en un paciente con anemia refractaria con exceso de blastos tipo 2 refractario a 5-azacitidina tratado con deferasirox y agentes estimuladores de colonias"],"prefix":"10.1016","volume":"142","author":[{"given":"Breno","family":"Moreno de Gusm\u00e3o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Guinea de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Perez-Persona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Oiartzabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.04.023_bib0005","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3324\/haematol.2011.048546","article-title":"Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients","volume":"97","author":"Gattermann","year":"2012","journal-title":"Haematologica"},{"issue":"Supl 5","key":"10.1016\/j.medcli.2013.04.023_bib0010","article-title":"Gu\u00edas espa\u00f1olas de diagn\u00f3stico y tratamiento de los s\u00edndromes mielodispl\u00e1sicos y la leucemia mielomonoc\u00edtica cr\u00f3nica","volume":"97","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2013.04.023_bib0015","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.leukres.2012.04.006","article-title":"Improved survival in MDS patients receiving iron chelation therapy\u2013A matched pair analysis of 188 patients from the D\u00fcsseldorf MDS registry","volume":"36","author":"Neukirchen","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2013.04.023_bib0020","unstructured":"National Cancer Institute (2010). Mielodysplastic syndromes (PDQ)-Health Professional Version 2. Disponible en: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf"},{"key":"10.1016\/j.medcli.2013.04.023_bib0030","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.leukres.2010.06.013","article-title":"Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes","volume":"34","author":"Greenberg","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2013.04.023_bib0035","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.leukres.2010.11.027","article-title":"Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review","volume":"35","author":"Guariglia","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2013.04.023_bib0040","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.leukres.2012.03.018","article-title":"Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors","volume":"36","author":"Pullarkat","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2013.04.023_bib0045","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2010.34.1222","article-title":"Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome","volume":"30","author":"List","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.04.023_bib0050","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3324\/haematol.2009.016824","article-title":"Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging","volume":"95","author":"Messa","year":"2010","journal-title":"Haematologica"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313003060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313003060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:27:25Z","timestamp":1539563245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313003060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0025775313003060"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.04.023","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}